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Abstract
Background: Smoking is the major etiologic factor in COPD, yet the exact underlying pathogenetic mechanisms
have not been elucidated. Since a few years, there is mounting evidence that a specific immune response, partly
present as an autoimmune response, contributes to the pathogenesis of COPD. Increased levels of anti-Hep-2
epithelial cell and anti-elastin autoantibodies as well as antibodies against airway epithelial and endothelial cells
have been observed in COPD patients. Whether the presence of these autoantibodies contributes to the
pathogenesis of COPD is unclear.
Methods: To test whether induction of autoantibodies against lung matrix proteins can augment the smoke-
induced inflammatory response, we immunized mice with a mixture of the lung extracellular matrix (ECM) proteins
elastin, collagen, and decorin and exposed them to cigarette smoke for 3 or 6 months. To evaluate whether the
immunization was successful, the presence of specific antibodies was assessed in serum, and presence of specific
antibody producing cells in spleen and lung homogenates. In addition, the presence of inflammatory cells and
cytokines was assessed in lung tissue and emphysema development was evaluated by measuring the mean linear
intercept.
Results: We demonstrated that both ECM immunization and smoke exposure induced a humoral immune
response against ECM proteins and that ECM immunization itself resulted in increased macrophage numbers in the
lung. The specific immune response against ECM proteins did not augment the smoke-induced inflammatory
response in our model.
Conclusions: By demonstrating that smoke exposure itself can result in a specific immune response and that
presence of this specific immune response is accompanied by an influx of macrophages, we provide support for
the involvement of a specific immune response in the smoke-induced inflammatory response as can be seen in
patients with COPD.
Background
Chronic Obstructive Pulmonary Disease (COPD) is a
leading cause of death worldwide with an increasing
morbidity and mortality [1]. Smoking is the most impor-
tant risk factor for the development of COPD and
smoking cessation is currently the most effective treat-
ment to diminish the accelerated lung function decline
associated with COPD. The exact pathogenetic mechan-
isms underlying the smoke-induced chronic inflamma-
tory response in the lungs of COPD patients are still
largely unclear and this hampers the search for new and
more effective treatment strategies.
Since a few years, there is mounting evidence that a
specific immune response, partly present as an autoim-
mune response, contributes to the pathogenesis of
COPD. Oligoclonal CD4 T cells have been demon-
strated in lung tissue of severe COPD patients [2] as
well as an antigen specific Th1 response against lung
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in COPD. Additionally, B cells organized into lymphoid
follicles have been demonstrated in lung tissue of COPD
patients [4] and the number of follicle containing air-
ways increases with disease severity [5]. Vh gene analysis
of these B cells showed oligoclonality and somatic
hypermutations [4] supporting the presence of an anti-
gen specific B cell response in COPD.
It is not clear against which antigen (s) this specific
immune response in COPD is directed. We considered
three potential sources of antigens; 1) microbial anti-
gens, 2) cigarette smoke components or derivatives, or
3) auto antigens derived from degradation products of
the extracellular matrix [6]. We recently showed
increased percentages of class switched memory B cells
in peripheral blood of current smokers with or without
COPD compared to never and ex-smokers [7]. These
findings suggest the presence of an ongoing smoke-
induced specific immune response. With respect to auto
antigens, a high prevalence of autoantibodies against
Hep-2 epithelial cell has been reported in COPD [8,9]
as well as a high prevalence of autoantibodies against
airway epithelial cells [8], endothelial cells [10], lung
elastin [3], several immunogenic peptides [11] and cyto-
keratin 18 [12].
We propose that neo-antigens may arise during the
chronic inflammatory response in COPD due to lung
tissue destruction and/or continued smoke exposure.
These neo-antigens are recognized and evoke an antigen
specific immune response, characterized by antigen spe-
cific T-and B cells in the lung, organized into lymphoid
follicles and the presence of autoantibodies. We ques-
tion however, whether the presence of this specific
immune response subsequently augments the chronic
inflammatory response in COPD, thereby causing more
severe disease and autoimmunity, or whether it is just
an epiphenomenon of the ongoing inflammation and
destruction. To answer this question, autoimmune
animal models for COPD have to be developed. Tarase-
viciene-Stewart et al demonstrated that a specific
anti-endothelial immune response can induce emphy-
sema in an experimental animal model [13]. However,
they did not investigate whether this anti-endothelial
immune response can enhance the smoke-induced
inflammatory response and emphysema.
To test whether the induction of antibodies against
lung matrix proteins can augment the smoke-induced
immune response, we immunized mice with a mixture
of mouse decorin, lung elastin, and lung collagen and
exposed them to cigarette smoke for 3 or 6 months.
The levels of specific antibodies and antibody producing
cells were investigated as well as the levels of inflamma-
tory cells and cytokines and the development of
emphysema.
Methods
Study design
Female C57BL/6 mice (Harlan,Z e i s t ,t h eN e t h e r l a n d s )
were divided into seven groups containing 8-12 animals
per group (Table 1). The mice were immunized with
extracellular matrix proteins (ECM) and adjuvant or
with adjuvant alone and subsequently exposed to cigar-
ette smoke or sham exposure for 3 or 6 months. An
extra control group was added for the 3 months of
exposure to study the effect of ECM immunization sepa-
rately. This group received ECM immunization alone
and was not exposed to cigarette smoke.
Before, during and at the end of the experiment
blood was obtained via orbital punctures to measure
serum levels of ECM specific antibodies. The smoke
exposure protocol started one week after the last
immunization booster. Mice were sacrificed after 3 or
6m o n t h so fs m o k eo rs h a ms m o k ee x p o s u r e .T h et r a -
chea was cannulated, the right lung was ligated and
l u n gl o b e sw e r es n a p - f r o z e na n ds t o r e da t- 8 0 ° Cf o r
immunohistochemical or cytokine analyses. The left
lung was inflated and fixed for 24 h with formalin with
a constant pressure of 25 cm H2O for emphysema
measurements or freshly used for leukocyte isolation
to perform ELISPOT analysis. The spleen was removed
to freshly isolate leukocytes for ELISPOT analysis.
Experiments were approved by the Institutional
Animal Care and Use Committee of the University of
Groningen (IACUC-RuG).
Immunization procedure
Mice were immunized intraperitoneally with 100 μlo f
Sigma Adjuvant (Sigma-Aldrich, St. Louis, USA) alone or
in combination with 10 μg mouse lung collagen (Elastin
Products, Owensville, USA), 10 μg recombinant mouse
decorin (R&D Systems, Minneapolis, USA) and 10 μg
mouse lung elastin peptides (Elastin Products). Three and
Table 1 Groups with different treatments and exposures
Group Immunization Exposure
3 months of
exposure
Control Smoke Adjuvant Smoke
ECM Smoke ECM +
Adjuvant
Smoke
Control Sham
smoke
Adjuvant Sham
smoke
ECM Sham smoke ECM +
Adjuvant
Sham
smoke
6 months of
exposure
Control Smoke Adjuvant Smoke
ECM Smoke ECM +
Adjuvant
Smoke
Control Sham
smoke
Adjuvant Sham
smoke
Brandsma et al. BMC Pulmonary Medicine 2010, 10:64
http://www.biomedcentral.com/1471-2466/10/64
Page 2 of 106 weeks after the first immunization a booster immuniza-
tion was given with the same mixtures.
Smoke exposure
Mice were exposed nose only to 24 puffs of cigarette
smoke from two 2R1 reference cigarettes (University of
Kentucky) two times per day, for 5 days a week for 3 or
6 months, as described previously [4,14]. Sham exposed
mice were exposed to air under the same conditions.
ELISA for ECM specific antibodies
To measure serum levels of ECM specific antibodies,
96-well plates (Nunc maxisorp, Thermo Fisher Scienti-
fic, Denmark) were coated overnight at 4°C with col-
lagen (10 μg/ml), decorin (10 μg/ml) or elastin (25 μg/
ml) (similar proteins as used for the immunization).
Non specific binding was blocked with 0.2% skim milk
in PBS for 1.5 h at 37°C. Plates were then incubated
with 50 μl of diluted serum for 2 hours at 37°C, fol-
lowed by rat-anti-mouse IgG1-biotin (BD Pharmingen,
San Diego, USA) or goat-anti-mouse IgM-biotin (South-
ern Biotechnology, Birmingham, USA) for 2 hours at
37°C and AB complex (Dako, Glostrup, Denmark) for
30 min at room temperature. The presence of ECM
specific antibodies was visualized using 3,3,5,5, tetra-
methylbenzidine (TMB) substrate (Sigma) and analyzed
with the Varioskan microplate reader (Thermo Fisher
Scientific, Waltham, USA) using SkanIt software. One
sample with a high optical density value (OD) was
titrated in serial dilutions to obtain a standard curve.
This standard curve was used to convert the obtained
OD values into relative units.
Cell isolation and ELISPOT analysis
Single cell leukocytes suspensions were freshly isolated
from spleen and lung tissue. Spleens were grinded
between two microscopy slides and cell homogenates
were filtered to obtain single cell suspensions. Single cell
lung suspensions were obtained as described previously
[15]. Briefly, lungs were minced with a razor blade and
incubated in a shaking water bath for 90 min at 37°C in
digestion buffer containing RPMI 1640 medium supple-
mented with 10% fetal calf serum (FCS) (both Lonza,
Verviers, Belgium), DNAse I (100 U/ml; Boehringer,
Mannheim, Germany), and collagenase I (250 U/ml;
Sigma-Aldrich). The digested lung tissue was passed
through a 70 μmc e l ls t r a i n e r( B D )a n ds u b s e q u e n t l y
centrifuged on a Percoll gradient (20-55%; GE Health-
care, Uppsala, Sweden). Cells were counted using a Sys-
mex PocH-100i cell counter (Sysmex, Roche, Germany).
For the ELISPOT analysis, 96-Wells plates (Nunc
maxisorp) were coated overnight at 4°C with collagen,
decorin or elastin (similar concentrations as used for
ELISA). The plates were washed with PBS/0.05%Tween
and blocked with 4% PBS/BSA. Isolated spleen and lung
cells (concentrations ranging from 0.25-1.10
6 cells) were
added to each well and incubated overnight at 37°C
with 5% CO2. The cells were removed by vigorous
washing with PBS followed by PBS/0.05%Tween. The
number of ECM specific antibody producing cells that
were present in spleen en lung tissue was identified by
adding rat-anti-mouse IgG1-biotin (BD Pharmingen) or
goat-anti-mouse IgM-biotin (Southern Biotechnology)
followed by Streptavidin-Alkaline Phosphatase (Dako)
and visualized as blue spots by using BCIP in agarose
(both Sigma). The number of spots was counted per
well and expressed as number of spots per million cells.
Histology
Total numbers of macrophages and neutrophils were
identified in frozen lung tissuew i t hs p e c i f i ca n t i b o d i e s
against CD68 (AbD Serotec, Düsseldorf, Germany) and
Gr-1 (BD Pharmingen). B cell and plasma cell numbers
were identified in formalin fixed and paraffin embedded
lung tissue with antibodies against B220 (BD Pharmin-
gen) and CD138 (BD Pharmingen) respectively. Total
cell numbers were counted at 25x magnification and
expressed as the number of positive cells per total sur-
face area lung tissue, which was assessed by morpho-
metric analysis using Leica Qwin image analysis
software (Leica Microsystems BV, Rijswijk, the
Netherlands).
The expression of collagen and decorin was identified
in formalin fixed and paraffin embedded lung tissue
with a Picro-Sirius red staining to visualize collagen and
a specific antibody against decorin (kind gift from Larry
Fisher, Bethesda, USA). The expression of elastin was
identified in frozen lung tissue with a specific antibody
against elastin (Cedarlane, Ontario, Canada). Collagen
bundles were visualized using polarized light. The
deposition of these extracellular matrix proteins in lung
tissue was scored semi-quantitatively.
Morphometrical evaluation of emphysema
Alveolar airspace enlargement was assessed on the for-
malin fixed and inflated lungs by mean linear intercept
(Lmi) by two independent individuals in a blinded man-
ner, as described previously [4,16].
Cytokines
Frozen lung tissue was homogenized in 50 mM Tris-
HCl buffer containing 150 mM NaCl and 0.002%
Tween-20 (pH 7.5) and centrifuged at 12000g for
10 min to remove any insoluble material. Concentrations
of IFN-g, IP-10, FGF basic, MIP-1a, MCP-1, VEGF, IL-5,
IL-2, GM-CSF, TNF-a, IL-10, IL-12, IL-13, IL-17, IL-1a,
IL-1b, IL-4, IL-6, KC and MIG in supernatants were
measured with a Biosource Mouse Cytokine 20 plex kit
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ELISA system (Lincoplex Systems, St Charles, MO, USA).
Statistics
Mann Whitney U tests were used to compare the differ-
ence between the groups. A value of p < 0.05 was con-
sidered significant.
Results
ECM immunization and smoke exposure increase serum
levels of specific antibodies
After 3 months of exposure, increased levels of anti-dec-
orin and anti-collagen IgM antibodies were present in
ECM immunized mice. This ECM effect was present in
both smoke- and sham smoke exposed mice (Figure 1A).
There was no effect of ECM immunization on the levels
of anti-elastin IgM antibodies in the 3 months exposed
mice.
After 6 months of exposure, increased levels of anti-
decorin and anti-collagen IgM antibodies were present
in ECM immunized smoking mice when compared to
control immunized smoking mice or control immunized
sham smoke exposed mice (Figure 1B). For elastin, there
was only an increase in IgM antibody levels in ECM
immunized smoking mice when compared to control
immunized sham smoke exposed mice. For decorin,
there were also increased levels of IgG1 and IgG2a anti-
bodies present in the ECM immunized smoke exposed
mice when compared to control immunized smoking
mice or control immunized sham smoke exposed mice
(Figure 1C).
Additionally, smoke exposure itself increased the levels
of IgM antibodies against collagen and decorin after 3
months of exposure and against collagen and elastin
after 6 months of exposure.
ECM immunization and smoke exposure increase the
numbers of specific antibody producing cells in spleen
and lung
After 3 months of exposure, increased numbers of anti-
decorin IgM and IgG1 producing cells were present in
the spleen of ECM immunized mice. This ECM effect
was present in both smoke exposed and sham smoke
exposed mice (trend for IgM) (Figure 2A). There was no
effect of ECM immunization on the numbers of anti-
elastin IgM producing cells and anti-collagen IgM pro-
ducing cells could not be quantified in the 3 months
exposed mice.
After 6 months of exposure, increased numbers of
anti-decorin IgM and IgG1 producing cells were present
in both spleen and lung (only IgM) of ECM immunized
smoking mice when compared to control immunized
smoking mice or control immunized sham smoke
exposed mice (Figure 2B, C). For collagen there was an
increase in IgM antibody producing cells in the lung
and spleen (trend) in the ECM immunized smoking
mice when compared to control immunized sham
smoke exposed mice and in the lung there was a similar
trend for elastin. Additionally, 6 months of smoke expo-
sure increased the numbers of anti-collagen IgM produ-
cing cells in both spleen and lung.
Smoking increases the numbers of macrophages, B cells
and plasma cells in lung tissue; no additional effect of
ECM immunization
Both 3 and 6 months of smoke exposure caused an
increase in the numbers of macrophages in lung tis-
sue (Figure 3A, control immunized smoking mice
and ECM immunized smoking mice compared to
control immunized sham smoke exposed mice). In
addition, the results of the 3 months exposed mice
show that ECM immunization alone also increased
the numbers of macrophages in lung tissue (control
immunized and sham smoke exposed compared to
ECM immunized and sham smoke exposed). There
was no additional effect of ECM immunization on
the numbers of macrophages in lung tissue compared
to the effect of smoking alone (control immunized
smoking mice compared to ECM immunized smok-
ing mice).
Six months of smoke exposure caused an increase in
the numbers of B cells and plasma cells in lung tissue
(Figure 3B and 3C, control immunized smoking mice
compared to control immunized and sham smoke
exposed mice). This effect was not present after 3
months of smoke exposure. There was no (additional)
effect of ECM immunizationo nt h ep r e s e n c eo fBc e l l s
and plasma cells in lung tissue (control immunized
smoking mice compared to ECM immunized smoking
mice). There were no effects of smoking or ECM immu-
nization on the numbers of neutrophils in lung tissue
(data not shown).
Smoking increases collagen deposition; no additional
effect of ECM immunization
After 6 months of smoke exposure there was an
increase in collagen deposition around vessels and air-
ways in the lungs of both control immunized and
ECM immunized smoking mice (Figure 4). There were
no effects of smoking or ECM immunization on dec-
orin and elastin deposition in the lung (data not
shown).
No effect of smoking and ECM immunization on
emphysema development
After 6 months of smoke exposure there was no signifi-
cant emphysema development, nor was there an (addi-
tional) effect of ECM immunization (Figure 5).
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tissue and ECM immunization increases the levels of FGF
basic and VEGF
Both 3 and 6 months of smoke exposure increased the
levels of IL-1a and IL-12 in lung tissue (Figure 6 control
immunized smoking mice compared to control immu-
nized and sham smoke exposed mice). In the 3 months
exposed mice this smoke effect is also present in the
ECM immunized mice (ECM immunized smoking mice
compared to ECM immunized sham smoke exposed
mice). There was no (additional) effect of ECM immuni-
zation on these cytokines.
In the 3 months exposed mice, ECM immunization
increased the levels of FGF basic and VEGF in the
sham exposed mice. For FGF basic this effect was also
present in the 3 and 6 months smoke exposed mice.
Additionally, 3 and 6 months of smoke exposure
decreased the levels of FGF basic and there was a simi-
lar trend for VEGF. There were no effects of smoking
or ECM immunization on IL-2, IL-10 and MIG (data
not shown). The levels of GMCSF, IL-1b,I L - 4 ,I L - 5 ,
IL-6, IL-13, IL-17, IP-10, KC, MCP-1, MIP-1a,a n d
TNF-a in lung tissue were at or below the detection
limit of the assay.
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Figure 1 Serum levels of ECM specific antibodies. Serum levels of IgM (A,B), and IgG1 and IgG2a (C) antibodies against decorin, collagen and
elastin are depicted. In A) the levels of the ECM specific antibodies are shown for the 3 months exposed mice. In B) and C) the levels of ECM
specific antibodies are shown for the 6 months exposed mice. Below the figures the different exposures are indicated; Control = control
immunization with adjuvant, ECM = immunization with ECM proteins, Smoke = smoke exposure, Sham smoke = control exposure to air. Smoke
exposed mice are indicated with black symbols and sham smoke exposed mice with open symbols. * indicates p < 0.05.
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Our study shows that immunization with mouse lung
decorin, elastin and collagen effectively increases serum
levels of specific antibodies and antibody producing cells
against these proteins in the spleen and lung. However,
these specific antibodies and specific antibody producing
cells did not augment the smoke-induced inflammatory
response in our mouse model. Interestingly, smoke
exposure also increased levels of specific antibodies in
serum and anti-collagen antibody producing cells in
spleen and lung, and ECM immunization increased
numbers of macrophages in the lung.
The effect of immunization with lung matrix proteins
on subsequent antibody production was most prominent
for decorin. Immunization resulted in high IgM, IgG1
and IgG2a antibody levels in serum as well as IgM and
IgG1 antibody producing cells in the spleen and IgM
a n t i b o d yp r o d u c i n gc e l l si nt h el u n g .T h ep r e s e n c eo f
anti-decorin IgM antibody producing cells in the lung is
of particular interest, since it reflects both systemic and
local pulmonary effects of immunization. The latter may
be crucial in contributing tot h ec h r o n i ci n f l a m m a t o r y
response in the lung and the diminished presence of
decorin around the airways, as we previously demon-
strated in patients with severe COPD [17]. The presence
of a specific IgG response against decorin is a result of
class switch recombination and suggests that the booster
immunizations with decorin evoked a strong secondary
immune response. The immune responses for collagen
and elastin were less strong and we did not find evi-
dence for class switch recombination.
In addition, we observed an increase in macrophage
numbers in the ECM immunized mice that were not
exposed to cigarette smoke. This is compatible with
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Figure 2 ECM specific antibody producing cells. The numbers of IgM (A,B,C) and IgG1 (B) antibody producing cells against decorin, collagen
and elastin in spleen (A,B) and lung (C) are depicted. In A) the numbers of anti-decorin IgM and IgG1 antibody producing cells in spleen are
shown for the 3 months exposed mice. In B) the numbers of anti-decorin, -collagen -and elastin IgM antibody producing cells and anti-decorin
IgG1 antibody producing cells in spleen are shown for the 6 months exposed mice. In C) the numbers of anti-decorin, -collagen -and elastin
IgM antibody producing cells in lung are shown for the 6 months exposed mice. * indicates p < 0.05.
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neutrophil numbers and MMP9 and MMP12 levels in
mice immunized with elastin peptides [18]. These find-
ings indicate that the induction of a specific immune
response against ECM proteins itself can evoke a
“COPD like” inflammatory response in the lung.
Interestingly, smoke exposure itself also induced a
specific IgM immune response against collagen and elas-
tin, which is in line with our previous findings showing
higher levels of class switched memory B cells in current
smokers than in ex- and never smokers [7]. Both reflect
a smoke induced specific immune response.
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Figure 3 Inflammatory cells in lung tissue. The numbers of macrophages (A), B cells (B) and plasma cells (C) in lung tissue are shown for the
3 (left) and 6 months (right) exposed mice. * indicates p < 0.05.
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Page 7 of 10Against our expectations, the increased level of anti-
ECM antibodies and antibody producing cells in the
spleen and lung of ECM immunized mice was not asso-
ciated with enhancement of the smoke-induced inflam-
matory response in this model. There can be several
explanations for these findings. First, 6 months of
smoke exposure did not evoke a very strong inflamma-
tory response, i.e. no increase in neutrophils and no sig-
nificant emphysema development. Therefore, one may
argue whether the effects of smoking were strong
enough to investigate if anti-ECM antibodies can aug-
ment the smoke-induced inflammatory response. We
have used the same mouse strain, gender, housing con-
ditions, and smoking model as before [4]. The only
difference is that there were some years in between the
two studies and thus a different batch of C57BL/6 mice
was used and the cigarettes were older. Apart from that
we do not have a clear explanation for the current lack
of effect on inflammation and emphysema.
Secondly, we also observed a specific immune
response against collagen and elastin in smoking mice,
resulting in similar anti-collagen and anti-elastin
immune responses as in the ECM immunized smoking
mice. Thus, if the specific immune responses against
collagen and elastin would have had an augmenting
effect on the smoke-induced immune response, it might
have been very difficult to detect. On the other hand,
the immune response against decorin was very strong in
the ECM immunized smoking mice and differed signifi-
cantly from the smoking mice. Therefore, the lack of an
effect of ECM immunization may indicate that a specific
immune response against decorin does not augment the
smoke-induced inflammatory response in this model.
However, compared to the human situation, where dif-
ferences in decorin expression and modulation of dec-
orin production are particularly present in patients with
severe COPD [17,19], one could still argue that the
effect of the specific anti-decorin response might be pre-
s e n ta f t e rl o n g e rs m o k ee x p o s u r eo ri nam o d e lw i t h
stronger effects of smoking.
Finally, the choice of ECM antigens could have influ-
enced our results. The use of elastin peptides and lung
collagen was based on previous data of Lee and
Goswami et al [3,18] and the use of decorin on our pre-
vious results of diminished peribronchial decorin
expression in COPD [17]. It can be envisaged that the
neo-antigens that arise during the chronic inflammatory
response in COPD differ in their protein conformation
from ECM proteins expressed in normal lung tissue and
Figure 4 Collagen deposition in lung tissue. The semi quantitative score for the collagen deposition in lung tissue is shown for the 6 months
exposed mice (left). * indicates p < 0.05. On the right an example of collagen deposition in lung tissue is shown.
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Figure 5 Emphysema development. The mean linear intercept
score, a measure for emphysema, is shown for the 6 months
exposed mice.
Brandsma et al. BMC Pulmonary Medicine 2010, 10:64
http://www.biomedcentral.com/1471-2466/10/64
Page 8 of 10IL-1α in lung tissue
3 months of exposure
Control ECM Control ECM
0
1000
2000
3000
4000
5000
       ---- Smoke ----   ---- Sham smoke ----
*
*
*
*
I
L
-
1
α
 
p
g
/
m
l
IL-12 in lung tissue
3 months of exposure
Control ECM Control ECM
0
500
1000
1500
       ---- Smoke ----   ---- Sham smoke ----
*
*
*
*
I
L
-
1
2
 
p
g
/
m
l
FGF basic in lung tissue
3 months of exposure
Control ECM Control ECM
0
5000
10000
15000
20000 p=0.08
*
*
*
       ---- Smoke ----   ---- Sham smoke ----
*
F
G
F
 
b
a
s
i
c
 
p
g
/
m
l
VEGF in lung tissue
3 months of exposure
Control ECM Control ECM
0
2000
4000
6000 *
*
*
       ---- Smoke ----   ---- Sham smoke ----
V
E
G
F
 
p
g
/
m
l
IL-1α in lung tissue
6 months of exposure
Control ECM Control
0
1000
2000
3000
4000
5000
*
*
    ------ Smoke ------     - Sham smoke -
I
L
-
1
α
 
p
g
/
m
l
IL-12 in lung tissue
6 months of exposure
Control ECM Control
0
200
400
600
800
1000
    ------ Smoke ------     - Sham smoke -
*
*
I
L
-
1
2
 
p
g
/
m
l
FGF basic in lung tissue
6 months of exposure
Control ECM Control
0
2000
4000
6000
8000
10000
    ------ Smoke ------     - Sham smoke -
*
*
*
F
G
F
 
b
a
s
i
c
 
p
g
/
m
l
VEGF in lung tissue
6 months of exposure
Control ECM Control
0
2000
4000
6000
8000 p=0.07
    ------ Smoke ------     - Sham smoke -
V
E
G
F
 
p
g
/
m
l
Figure 6 Cytokine levels in lung tissue. The levels of IL-1a, IL-12, FGF basic and VEGF in lung tissue are shown for the 3 (left) and 6 months
(right) exposed mice. * indicates p < 0.05.
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Page 9 of 10that only neo-antigens can be recognized by the
immune system. Because we induced antibodies against
the original conformation of collagen and decorin and
against elastin peptides, it is uncertain whether their
cognate antigen epitopes are present in the lungs of
smoking mice and whether these antibodies actually can
evoke a local immune response.
Conclusions
We showed that both ECM immunization and smoke
exposure induced a specific immune response against
ECM proteins and that ECM immunization itself
increased macrophage numbers. The presence of a spe-
cific immune response against ECM proteins did not
augment the smoke-induced inflammatory response in
our model. This does not necessarily imply that there is
no causal role for autoantibodies in augmenting the
smoke-induced inflammatory response in COPD. The
lack of an additive effect of autoantibodies and smoking
in our study can well be due to a combination of a
weak inflammatory response after smoking, the choice
of antigens, and the fact that smoke exposure itself
already caused an antibody response in our model. The
development of additional autoimmune mouse models
for COPD will be necessary to further investigate
whether the specific immune response in COPD is a
true autoimmune response contributing to the develop-
ment of more severe disease.
Acknowledgements
We thank Pieter Klok, Floor Spaans and our colleagues from the Central
Animal Facility for their assistance with performing the smoke experiments.
This study was funded by the Dutch Asthma Foundation (3.2.06.075)
Author details
1Department of Pathology and Medical Biology, University Medical Center
Groningen, University of Groningen, Groningen, the Netherlands.
2Department of Pulmonary Diseases, University Medical Center Groningen,
University of Groningen, Groningen, the Netherlands.
Authors’ contributions
CB participated in the study design, performed the animal experiments,
analyzed the data, performed statistical analysis and drafted the manuscript.
MG and HJ carried out all the experimental analyses and were involved in
the data analyses. WT, DS, MH and HK were involved in the study design
and helped to draft the manuscript. All authors approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 June 2010 Accepted: 13 December 2010
Published: 13 December 2010
References
1. Global Strategy for the Diagnosis, Management and Prevention of
COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD).
2009 [http://www.goldcopd.org].
2. Sullivan AK, Simonian PL, Falta MT, Mitchell JD, Cosgrove GP, Brown KK,
et al: Oligoclonal CD4+ T cells in the lungs of patients with severe
emphysema. Am J Respir Crit Care Med 2005, 172:590-596.
3. Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, et al:
Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat
Med 2007, 13:567-569.
4. van der Strate BW, Postma DS, Brandsma CA, Melgert BN, Luinge MA,
Geerlings M, et al: Cigarette smoke-induced emphysema: a role for the B
cell? Am J Respir Crit Care Med 2006, 173:751-758.
5. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al: The
nature of small-airway obstruction in chronic obstructive pulmonary
disease. N Engl J Med 2004, 350:2645-2653.
6. Brusselle GG, Demoor T, Bracke KR, Brandsma CA, Timens W: Lymphoid
follicles in (very) severe COPD: beneficial or harmful? Eur Respir J 2009,
34:219-230.
7. Brandsma CA, Hylkema MN, Geerlings M, van Geffen WH, Postma DS,
Timens W, et al: Increased levels of (class switched) memory B cells in
peripheral blood of current smokers. Respir Res 2009, 10:108.
8. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MW,
Csizmadia E, et al: Autoantibodies in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2008, 177:156-163.
9. Bonarius HP, Brandsma CA, Kerstjens HA, Koerts JA, Kerkhof M,
Nizankowska-Mogilnicka E, et al: Antinuclear autoantibodies are more
prevalent in COPD in association with low body mass index but not
with smoking history. Thorax 2010.
10. Karayama M, Inui N, Suda T, Nakamura Y, Nakamura H, Chida K:
Antiendothelial Cell Antibodies in Patients With COPD. Chest 2010,
138:1303-1308.
11. Leidinger P, Keller A, Heisel S, Ludwig N, Rheinheimer S, Klein V, et al: Novel
autoantigens immunogenic in COPD patients. Respir Res 2009, 10:20.
12. Kuo YB, Chang CA, Wu YK, Hsieh MJ, Tsai CH, Chen KT, et al: Identification
and clinical association of anti-cytokeratin 18 autoantibody in COPD.
Immunol Lett 2010, 128:131-136.
13. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Moore M, Sullivan A,
Nicolls MR, et al: An animal model of autoimmune emphysema. Am J
Respir Crit Care Med 2005, 171:734-742.
14. Brandsma CA, Hylkema MN, van der Strate BW, Slebos DJ, Luinge MA,
Geerlings M, et al: Heme oxygenase-1 prevents smoke induced B-cell
infiltrates: a role for regulatory T cells? Respir Res 2008, 9:17.
15. Hylkema MN, Hoekstra MO, Luinge M, Timens W: The strength of the
OVA-induced airway inflammation in rats is strain dependent. Clin Exp
Immunol 2002, 129:390-396.
16. Brandsma CA, Hylkema MN, Luinge MA, Geerlings M, Klok PA, Cassee FR,
et al: Nitrogen dioxide exposure attenuates cigarette smoke-induced
cytokine production in mice. Inhal Toxicol 2008, 20:183-189.
17. van Straaten JF, Coers W, Noordhoek JA, Huitema S, Flipsen JT,
Kauffman HF, et al: Proteoglycan changes in the extracellular matrix of
lung tissue from patients with pulmonary emphysema. Mod Pathol 1999,
12:697-705.
18. Goswami S, Barranco W, Lee SH, Grudo A, Corry DB, Kheradmand F: An
autoimmune basis in the disease pathogenesis of COPD/emphysema.
The Journal of Immunology 178 2007, Abstract.
19. Noordhoek JA, Postma DS, Chong LL, Menkema L, Kauffman HF, Timens W,
et al: Different modulation of decorin production by lung fibroblasts
from patients with mild and severe emphysema. COPD 2005, 2:17-25.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2466/10/64/prepub
doi:10.1186/1471-2466-10-64
Cite this article as: Brandsma et al.: Induction of autoantibodies against
lung matrix proteins and smoke-induced inflammation in mice. BMC
Pulmonary Medicine 2010 10:64.
Brandsma et al. BMC Pulmonary Medicine 2010, 10:64
http://www.biomedcentral.com/1471-2466/10/64
Page 10 of 10